E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
[Conditions, controversies and contradictions between Central Sensitivity Syndrome and Depressive Disorders].
Maresca, Tomás, Covini, Elvira, Mato, Andrea Márquez López · Vertex (Buenos Aires, Argentina) · 2013
Quick Summary
This review article explains Central Sensitivity Syndrome (CSS), a condition where the nervous system becomes overly sensitive to pain and other stimuli, and how it relates to ME/CFS and fibromyalgia. The authors describe how CSS differs from depression, even though people with CSS often experience depression as well, by comparing how the body's stress hormones, sleep patterns, and immune systems function differently in each condition.
Why It Matters
This study helps clarify why ME/CFS and fibromyalgia patients often receive misdiagnoses of depression and why standard antidepressant treatments may be ineffective, potentially leading to better recognition and more appropriate medical management of these conditions.
Observed Findings
- Central Sensitivity Syndrome shows hypoactive adrenal function with DST hypersuppression, while depression shows hyperactive HPA axis with DST non-suppression
- CSS features alpha-delta sleep intrusion, whereas depression disrupts REM latency and stages 3/4 sleep
- Immunoendocrine disturbances are opposite between CSS and depression, suggesting distinct pathophysiology despite clinical overlap
- Thyroid hormone metabolism differs: CSS shows probable reverse T3 elevation versus depression's flat TSH response curve
Inferred Conclusions
- Central Sensitivity Syndrome (including ME/CFS and fibromyalgia) is neurobiologically distinct from depressive disorder despite frequent comorbidity
- Differential neuroendocrine, sleep, and immunological profiles can distinguish CSS from depression
- Clinical management of CSS requires a specialized approach different from treatment of primary mood disorders
Remaining Questions
- What are the primary triggers for central sensitization in ME/CFS versus fibromyalgia, and are they identical?
- Can the identified neuroendocrine and immune markers be developed into practical diagnostic tools for routine clinical use?
- Which medical specialty or multidisciplinary team structure is most effective for managing CSS in routine care settings?
What This Study Does Not Prove
This review does not present original experimental data or clinical trials, so it does not prove causation or establish new biomarkers. It synthesizes existing literature and does not validate a specific diagnostic test or treatment for CSS or ME/CFS.
Tags
Symptom:Unrefreshing SleepPainFatigueSensory Sensitivity
Biomarker:CytokinesNeuroimaging
Method Flag:Weak Case DefinitionExploratory Only
Metadata
- PMID
- 24312923
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →